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Abstract
Infectious diseases originate from pathogens and increased severely in current
years. Despite numerous important advances in antimicrobial therapy, the exten-
sive use and misuse of these antimicrobial drugs have caused the emergence of
microbial resistance, which is a serious risk to public health. In particular, the
emergence of multidrug-resistant pathogens has become a serious difficulty in the
therapy of pathogenic diseases. Therefore, the progress of novel drugs to deal with
resistant pathogens has become one of the most essential areas of antimicrobial
research today. In addition to the development of novel and efficient antimicrobial
agents against multidrug-resistant pathogens, recent attention has focused on the
treatment of tuberculosis. Therefore, recent developments have been directed
towards examining currently used and newly developed antimycobacterial drugs
and their toxicities and mechanism of action.
Keywords: Chemotherapy, epidemiology, tuberculosis, multidrug-resistant,
Mycobacterium
1. Introduction
Tuberculosis (TB) is a chronic infectious and zoonotic disease caused by the
Mycobacterium tuberculosis (Mtb) complex. It is responsible for a lung infection
(pulmonary TB) and other body parts (extrapulmonary TB) [1, 2]. TB is the second
cause of death next to human immunodeficiency virus (HIV) infection. TB is a
global public health disaster since 1993 at a time of expected 7–8 million cases and
1.3–1.6 million deaths occurred yearly. In 2010, 8.8 million new cases of TB and 1.1
million deaths from TB, and 0.35 million deaths from that HIV-allied TB and
worsen due to the maturity of anti-TB drug resistance (DR) [3]. The emergence of
resistance against anti-TB drugs is a barrier to the success of TB treatment. Inade-
quate TB treatment is responsible for the incident of DR-TB [4]. According to the
World health organization (WHO) report, TB has spread to every area of the world.
As much as one-third of the world’s population is presently infected, more than any
other infectious microbial disease [5]. These numbers however are only a partial
1
representation of the world TB threat. It was predictable that nearly 1 billion more
people will be infected with TB in the coming 20 years. However, the number of
new TB cases is still growing slowly, 95% occur in developing nations every year,
and about one million young women per year are offended with this infectious
disease in the developing world. The occurrence of TB is associated with a dense
population, deprived sanitation, and, poor diet [6]. Directly observed treatment,
short-course (DOTS), is the effective way of the control of TB. The three main anti-
TB drugs, isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA) are used. These
drugs are hepatotoxic and may cause drug-related hepatitis. Despite the success of
the DOTS therapy, the appearance of MDR-TB strains, persistently isolated from
the sputum of pateints, darkens the future [7]. The expansion in TB incidence
during current years is primarily due to the incidence of TB in synergy with the HIV
pandemic, which increases the risk of growing the new TB cases were attributable
to HIV co-infection, and as well as the emergence of MDR-TB strains [8, 9]. There-
fore, the objective of this paper is to review the current status of antimycobacterial
drugs.
2. Etiology and routes of transmission
Tuberculosis (TB) is caused by the Mtb complex. The mycobacterium is non-
motile, Gram-positive, rod-shaped, obligate aerobic bacteria that belong to the
order Actinomycetales and family Mycobacteriaceae. This Mtb complex includes
(subspecies M. canetti), M. bovis, M. microti, M. africanum, M. caprae, M. bovis
BCG, andM. pinnipedii [10]. The cough in a TB patient is caused by the infection of
Mtb and distributed to air during coughing. The healthy persons who inhaled air
droplets of TB infected person and make contact become infected [11].
Tuberculosis-HIV Combination:
The current opinion disclosed that one-third of the 42 million people living with
HIV/AIDS all around the world are co-infected with TB. As per the WHO report,
about 90% of the patients containing both TB and HIV died within only some
months after clinical indications have arisen. Thus, WHO warned the world of the
“even bigger TB-HIV crisis” and explained for extensive accessibility of free anti-
TB drugs to individuals living with HIV. The HIV cases are spreading quickly in
India with the biggest number of TB cases all around the world [12–15].
3. Chemotherapy of tuberculosis
First-line anti-TB drugs:
Treatment of TB is mainly dependent on first-line anti-TB drugs (Figure 1),
which comprises SM, INH, RMP, EMB, and PZA, these are more effective and less
toxic effects as compare to second-line anti-TB drugs [15].
Second-line anti-TB drugs:
According to the WHO, there are six drugs of second-line anti-TB drugs. These
drugs are categorized as second-line anti-TB drugs due to one of two potential
reasons: 1) they are less active than the first-line anti-TB drugs or more toxic side-
effects or 2). These drugs involve different classes namely, aminoglycosides
(Figure 1): (kanamycin, amikacin), polypeptide analogs (Figure 2): (viomycin,
capreomycin), FQs (Figure 3): (CPX, MXF, OFX, etc), thioamides: (prothioamide,
ethionamides), cycloserine and para-aminosalicylic acid (Figure 4) [2–4].
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Drugs for HIV/TB
Clarithromycin (Figure 5) is a macrolide antibiotic drug used in HIV infected
TB patients to cure the M. avium complex (MAC). It has an analogous of
erythromycin but is more efficient against certain Gram-negative bacteria, mainly
Legionella pneumophila. Thioacetazone (Figure 5) is valuable in stopping resistance
to more influential drugs like INH and RIF. It is not at all used on its own to treat
TB. It uses is declining because it can originate severe skin reactions in HIV
positive patients. It is also identified to kill MDR-TB. It is no longer suggested
for treatment due to its adverse effects like urination-difficulties, dry mouth,
glaucoma, and postural hypotension. The circumstances are further complex by
the emergence of MDR-TB and XDR-TB by infections with lethal synergy with
HIV/AIDS [4, 15].
Figure 1.
Structures of first-line anti-TB drugs.
Figure 2.
Structures of different antibiotics (second-line drugs).
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4. Properties and mechanism of currently used common anti-TB drugs
4.1 Primary agents
Isoniazid (Nydrazid, Laniazid)
It is a bacteriostatic drug against resting cells and bactericidal against dividing
microorganisms. Isoniazid (INH) is an anti-TB drug since 1952 and acts as a bacte-
ricidal and bacteriostatic for rapidly and slowly growing bacilli. It diffuses across the
Mtb cell membrane [16]. The INH targets KatG and inhA gene. KatG gene encodes
catalase/peroxidase enzyme that activates prodrug and peroxynitrite that are
involved in pathways of reactive nitrogen and oxygen intermediates [17, 18]. InhA
gene encodes NADH dependent enoyl-Acyl Carrier Protein (ACP)-reductase that
causes inhibition of mycolic acid synthesis [19, 20]. The INH is a close to ideal
antibiotic and very selective (MIC value 0.025–0.05 μg/mL and other bacteria
MIC vale >500 μg/mL). The INH has good oral availability and low toxicity. It
Inhibits mycolic acid biosynthesis and targets the enoyl-acyl carrier protein reduc-
tase enzyme (InhA) engaged in mycolic acid synthesis. The INH inactivation of
Figure 3.
Structures of different fluoroquinolones (second-line anti-TB drugs).
Figure 4.
Structures of different second-line anti-TB drugs.
Figure 5.
Structures of drugs for HIV/TB.
4
Molecular Epidemiology Study of Mycobacterium Tuberculosis Complex
IhhA needs metabolic activation. It is also utilized in combinations, INH and RIF
and INH, RIF, and PZA.
Rifampicin
Rifampicin (RIF) was isolated from Streptomyces mediterranei from the soil sam-
ple and used as an anti-TB since 1972 [21]. It is still utilized as the best choice of
anti-TB drugs. RIF diffuses across Mtb cell membrane due its lipophilic nature. RIF
inhibits the mycobacterial transcription by binds to the β-subunit of DNA-
dependent-RNA polymerase [22–24].
Rifamycins
Rifamycins are natural products from Amicolaptosis mediterranei belong
ansamycin family and are. These are active towards various bacteria but used
almost exclusively against TB [2–4].
Rifampin (Rifadin)
Rifampin is a semisynthetic analog of rifamycin and the most effective anti-TB
agent with MIC values as low as 0.005 μg/mL. It is used as an oral or parenteral
formulation, it can access CNS and it is sensitive to moisture [2–4].
Rifapentine (Priftin)
Rifapentine is a cyclopentyl analog of RIF. The benefit over rifampin is
less repeated dosing. It inhibits bacterial DNA-dependent RNA polymerase and
binds to the β subunit. The RIFs blocks the elongation of the RNA transcript
and inhibits gene expression. It also acts as a CYP450 inducer. One remarkable
side effect is the discoloration of body fluids. The RIFs are not suggested for
use in HIV infected patients. Two RIF analogs are existing for indications other
than TB [2–4].
a. Rifabutin (Mycobutin): It is used mostly in MAC infections [2–4].
b. Rifaximin (Xifaxan): Indicated for the treatment of traveler’s diarrhea [2–4].
Ethambutol (Myambutol):
Ethambutol (EMB) is a bacteriostatic, active against growing bacilli, and used as
an anti-TB drug in 1966. It obstructs polymerization of cell wall component
lipoarabinomannan and arabinogalactan that interrupted biosynthesis of
darabinofuranosyl-P-decaprenol and produced bacteriostatic effect [25, 26]. EMB
(+) isomer is orally active, 16 times more potent than meso isomer, and 200 times
more potent than () isomer. The EMB inhibits the polymerization of cell wall
arabinan and results in the addition of the lipid carrier deca-prenol
phosphoarabinose. The EMB interferes with the transfer of arabinose to the cell wall
acceptors. EMB is effective only towards energetically dividing cells and its action is
synergistic with RIF. Arabinosyl transferase enzyme is a target for the action of
EMB in both Mtbs and M. avium. The enzyme is encoded by the embCAB gene
organized as an operon and engaged in the arabinogalactan synthesis [27, 28].
Pyrazinamide (Aldinamide)
Pyrazinamide (PZA) is a pyrazine derivative of nicotinamide and its mechanism
is assumed to be analogous to INH. It has to be metabolically activated and PZA-
resistant strains of Mtb contain a mutation in the hydrolase gene. PZA activity
against Mtb depends on the anaerobic and acidic conditions. PZA is activated to
pyrazine acid by the pyrazinamide/nicotinamidase that encoded by gene pncA [29].
Acidic condition favors the production of protonated pyrazinoic acid that collected
in the Mtb cell membrane which interrupts cell membrane potential and altered
membrane transport [30]. The new target of PZA’, clpC1 (Rv3596c) that encodes
an ATP-dependent ATPase is liable for protein degradation by the complex struc-
ture with protease clpP1 and clpP2 [31, 32].
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Streptomycin
Streptomycin (STR) is the first antibiotic cure for TB and it is isolated from the
soil microbe Streptomyces griseus in 1943 [1]. It is active against growing bacilli, but
not active against intracellular and non-growing bacilli. STR is still considered a first-
line anti-TB drug but is used less frequently than the other drugs. It has no action
againstM. avium. Resistance is frequently due to phosphorylation. It targets both rpsl
and rrs genes that encode 30S ribosomal protein S12 and 16S rRNA, respectively, and
finally inhibit the instigation of the translation in the protein synthesis [33, 34].
Secondary/Retreatment Agents:
Aminosalicylic Acid (P.A.S. Parasal):
Para-aminosalicylic acid (PAS) is an oral drug that fell out of use because of
adverse effects and frequent resistance. Related to sulfonamides, it is bacteriostatic
and acts as a competitive inhibitor of mycobacterial dihydropteroate synthase.
There are two mechanisms to produce the desired effect. First, it inhibited folic acid
synthesis by the inhibiton of dihydrofolate synthase and dihydropteroate synthase
that produces hydroxyl dihydrofolate antimetabolite responsible for the folic acid
synthesis [35]. Secondly, it reduced the uptake of iron, that is essential for cell wall
component mycobactin synthesis [15].
Ethionamide (Trecator SC):
Ethionamide (ETH) is developed as a derivative of INH but less potent than
INH. Two genes play a role in the mechanism of actions ETH is ethA and inhA.
EthA is regulated by the transcriptional repressor ETH [36]. The mechanism of
action is like INH. The oxidative activation comes into sight it is by an enzyme other
than KatG projected to form a covalent connection with InhA. The mechanism of
action of the ETH is a disruption of mycolic acid synthesis by which
monooxygenase enzyme activated ETH that binds to NAD+ and forms an adduct
which inhibits enoyl acyl-ACP reductase enzyme [37–39] (Figure 6).
Cycloserine (Seromycin):
Cycloserine (CYS) is a natural compound and restricted to being retreatment
because of CNS toxicity. CYS is a cyclic derivative of serine hydroxamic acid and
terizidone. It is isolated from Streptomyces orchidaceous in the 1950s. Its acts by
interrupting mycobacterial cell wall synthesis by inhibition of L-alanine racemase
encoded by alrA that forms D-alanine from L-alanine and D-phenylalanine synthe-
tase crucial for the production of peptidoglycan and cell wall synthesis by the
inclusion of Dalanine into pentapeptide [40, 41]. It inhibits peptidoglycan forma-
tion, particularly-blocks the alteration of L-Ala to D-Ala.
Figure 6.
Presently used anti-TB drugs and sites of action.
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Fluoroquinolones (FQs) are the derivative of chloroquine in the 1960s and were
used as bactericidal in human and veterinary medicines [42]. The FQs are acted by
blocking of mycobacterial DNA replication by binding to α and β subunits of DNA
gyrase (gyrA and gyrB), which catalyze the supercoiling of DNA and finally,
inhibits DNA synthesis [43].
Aminoglycosides and polypeptides
The aminoglycosides (amikacin, kanamycin) and polypeptides (capreomycin,
viomyocin) act by inhibiting protein synthesis. Kanamycin and amikacin alter 16S
rRNA and capreomycin and viomycin interfere with small and large subunits of the
70S ribosome [44, 45].
Capreomycin (Capastat)
Capreomycin belongs to the tuberactinomycin family, a highly basic cyclic
pentapeptide with a sixth amino acid side chain. It is the most active compound
of this family and blocks protein synthesis and interferes with initiation
tRNA selection and chain elongation. It binds to a site on 16S rRNA and the
23S rRNA. Some mycobacterium resistant to capreomycin is also resistant to
kanamycin [2–4].
Kanamycin
The most commonly used second-line aminoglycoside and only given by
intramuscular (IM) administration [14, 15].
Linezolid
Linezolid is an oxazolidinone derivative that interrupts the early stage in
protein synthesis by binding to the 23S rRNA of the 50S subunit. The gene rplC
and rrl are concerned in the action of Linezolid. The rplC gene that encodes 50S
ribosomal L3 protein to involve in the synthesis of the ribosomal peptidyl-
transferase. Hence, rrl gene has 3138 bp length that encodes 23S ribosomal
RNA [46].
5. Compounds originating from existing families of drugs
Fluoroquinolones
Fluoroquinolones (FQs) were established into clinical applications in the
1980s and extensively used for the treatment of various bacterial infections [47].
The FQs have been also originated to have anti-TB activity [48] and are presently
used as second-line anti-TB drugs. Cross-resistance has been accounted for within
the FQs class such that reduced vulnerability to one FQ possibly presented
reduced vulnerability to all FQ derivatives [49–51]. With the extensive use of FQSs
for the therapy of common microbial infection, resistance to FQs remains uncom-
mon and occurs mostly in MDR strains. The cross-resistance was observed among
the various FQ compounds tested (OFX, LVX, GAT, MXF, and CPX) [52]. The
rapid progress of resistance is mostly when FQs are used as the only active drugs in
a failing multi-drug therapy [53–55]. These new agents are currently taken in
concern as anti-TB drugs.
Gatifloxacin
Gatifloxacin (GAT) has bactericidal activity against Mtb [56]. It revealed the
highest bactericidal effect during the first 2 days. GAT was used in combination
with the first-line anti-TB drug INH or RIF: GAT was able to somewhat enhance the
bactericidal activity of INH or RIF only for the first 2 days [57]. One study reported
that when evaluated in mice in combination with ethionamide and PZA (high doses:
450 mg/kg, 5 days per week). The GAT was capable to clear the lungs of infected
animals after 2 months of therapy [58].
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Moxifloxacin
In-vitro moxifloxacin (MXF) show to kill a subpopulation of tubercle bacilli that
not killed by RIF, while the older FQs, (ciprofloxacin) CPX, and (ofloxacin) OFX
did not have any major bactericidal effect. The MXF obstructs protein synthesis in
gradually metabolizing bacteria through a mechanism that varies from that used by
RIF. In mice models, the effect of MXF against tubercle bacilli was comparable to
that of INH [59]. In combination with MXF and PZA has been killing the bacilli
more successfully than the INH + RIF + PZA combination [60]. The substitution of
MXF with INH in the standard drug therapy could relieve a probable antagonism
among the presently used drugs [61]. The MXF might be a promising candidate
drug to shorten TB treatment [62, 63].
Non-fluorinated quinolones
A series of 8-methoxy non-fluorinated quinolone analogs (NFQs) lack a 6-fluo-
rine atom in their quinolone ring distinguishing them from fluorinated quinolone
compounds such as GAT and MXF. The NFQs target a broad range of bacteria and
they appear to operate preferentially through inhibition of DNA gyrase. The NFQs
are presently being tested against Mtb [4].
Macrolides
The anti-TB effect of the macrolide antibiotics through the synthesis of addi-
tional chemically modified analog of erythromycin. Some analog were recognized as
anti-TB agent superior to the clarithromycin [4, 15].
New rifamycin derivatives
Rifalazil, a semisynthetic RIF, is described by a long half-life and is more effec-
tive than RIF and rifabutin against Mtb strains [64]. However, high-intensity RIF–
resistant strains present cross-resistance to all rifamycin drugs [65].
Bedaquiline or TMC207
Bedaquiline is a diarylquinoline and used bactericidal. Bedaquiniline involves
blocking the proton pump of ATP synthase ofMtb then depletes the energy demand
of both replicating and nonreplicating (dormant) mycobacteria and at the result in
cell death [66, 67].
Delamanid or OPC 67683
Delamanid is a dihydro-nitroimidazooxazole derivative and activated by
deazaflavin-dependent nitroreductase enzyme (Rv3547). It acts by interrupting the
mycobacterial cell wall component synthesis. Delamanid inhibits the methoxy- and
keto-mycolic acid synthesis which is a vital component of the Mtb cell wall. It is
active against both growing and nongrowing mycobacteria [68, 69].
PA-824
PA-824 is a nitroimidazole derivative and it activated by deazaflavin-dependent
nitroreductase like delamanid. Mechanism of action is not clearly konown but it
could be described as its activity in replicating and non-replicating mycobacteria. In
aerobically replicating cell PA-824 interrupts mycolic acid synthesis by the
collecting of hydroxymycolates instead of ketomycolates [70, 71]. In hypoxic non
replicating mycobacteria, PA-824 release nitric oxide (NO) that interferes with
cytochrome oxidase to disrupt the energy metabolism of the cell wall [72].
SQ-109
SQ-109 is an ethambutol analog and its mechanism of action is not known. It has
no inhibitory activition against the secreted Ag85 mycolyltransferase. Rather SQ-
109 causes collection of trehalose monomycolate a precursor of trehalose dimycolate
by obstructing accumulates of mycolic acids into theMtb cell wall core [73].
Antitubercular drugs with the new and different moiety
To investigating useful drug candidate’s currently in two major categories: Novel
chemical entity and compounds instigating from existing relatives of currently used
drugs, where novel chemistry is used to optimize the new compounds.
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Nitroimidazopyrans and Nitroimidaoxazoles derivatives
In this series, the lead molecules are CGI 17341 and PA824/PA1343 and inhibit
the cell wall synthesis. However, two key areas of concern also require to attend-
possible mutagenicity resulting from the presence of a nitro group, and the chance
for the development of drug resistance. The latter is encouraged by the reality that
the nitroimidazoles induce a high rate of mutation [2–4], leading to uncertainties
that this might cause the appearance of MDR bacteria. Since the drugs will certainly
be used in combination therapy [74].
Nitroimidazole PA-824
The PA-824 is a nitroimidazole derivative and used as anti-TB agent. PA-824
acts mainly as synthesis of cell wall components inhibitor. In vitro, PA-824 showed
high activity against drug-sensitive and MDR-TB strains, there is no cross-
resistance with currently used anti-TB drugs. Moreover, PA-824 has shown in-vitro
bactericidal activity against both replicating and static bacteria [4]. The PA-824
bactericidal effect against nonreplicating bacteria was equivalent to the RIF. Use of
PA-824 as monotherapy in mice and cause reduced bacterial counts in the lungs is
better than RIF or INH monotherapy. After 12 weeks of treatment with PA-824,
RIF, or INH, complete removal of the bacterial load was not getting in any of the
treated mice [2–4].
Nitroimidazoles CGI 17341
The CGI 17341 has substantial potential as anti-TB agent in a preclinical study.
In-vitro at 0.04 to 0.3 μg/ml, it inhibited both drug-susceptible and MDR-TB strains
and exhibited no cross-resistance with INH, RIF, SM, or EBM. In-vitro against Mtb,
its action was similar to that of INH and RIF and higher to SM, norfloxacin,
ciprofloxacin, and the oxazolidinone DuP 721. In Mtb-infected mice, oral treatment
with CGI 17341 on days 11 and 12 after infection resulted in an ED50 of 7.7 mg/kg
and showed a significant dose-dependent progress in survival time [75]. These
drugs were not mutagenic and showed potent activity against replicating and static
Mtb, including MDR strains.
Nitroimidazole OPC-67683
It is mycolic acid inhibitors and interferes with the biosynthesis of the myco-
bacterial cell wall. In vitro, OPC-67683 was exhibited high activity against drug-
sensitive as well as DR strains with MICs varying 6–24 ng/mL. There is no cross-
resistance with any of the current first-line anti-TB drugs. Moreover, OPC-67683
exhibited strong intracellular activity against the MtbH37Rv residing within human
macrophages and type II pneumocytes. The OPC-67683 is active against MtbH37v
and MDR-TB strains in-vivo starting from a concentration of 0.03125 mg/body [2–
4]. The OPC-67683 exhibited 6–7 fold elevated activity compared to first-line drugs
INH and RIF.
Imidazole Analogues
Miconazole is a well-known antifungal drug that has been accounted for to have
anti-TB activity in vitro against MtbH37Ra (MIC 2 μg/ml). It inhibiting replicating
bacteria and also has some effect on stationary phase bacilli [88]. Unfortunately,
miconazole is not active orally and therefore is little additional interest in
progressing TB indication [76].
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1,2,4-Triazoles
Various 1,2,4-triazoles have been estimated against Mtb H37Rv. Compound (1)
gave 61% inhibition at 6.25 μg/ml. Other triazole analogs were inactive [2–4].
Imidazo(4,5-c)pyridine compounds
A series of imidazo(4,5-c)pyridines, one compound (2) for common formula
(R1, R2 unrevealed)-inhibited MtbH37Rv and other strains with MICs range 0.256–
2.56 μg/ml. Imidazo(4,5-c)pyridines were initially prepared as anti-mitotic agents
but in the present work, fewer cytotoxic agents were chosen and found to have anti-
TB activity [4].
Diarylquinoline compounds
Diarylquinolines (DARQs) is structurally unlike both FQs and other quinolines
derivatives. The DARQ R207910 is a new class of anti-TB drugs. It has specificity
towards mycobacteria as well as atypical species, important in humans such as
MAC,M. kansai, and the fast-growingM. fortium andM. abscessus [77]. The anti-TB
specific spectrum differs from that of INH, which has very poor activity against
MAC. It will be extremely targeted to the treatment of TB infections, mainly
targeting the proton pump of ATP synthase [78].
Diarylquinoline TMC207
Diarylquinoline (DRQ) TMC207 is an exceptionally promising class of anti-TB
drugs. About, 20 compounds of the DRQ series have been exhibited a MIC value
below 0.5 μg/ml against Mtb H37Rv [78]. The most active compound of this class is
TMC207 against Mtb. The mechanism of action of DRQ TMC207 is different from
those of other anti-TB drugs involving a low probability of cross-resistance with
accessible anti-TB drugs. The DRQ TMC207 is capable to inhibit bacterial growth
against MDR-TB isolates and appears to act by inhibiting the ATP synthase [79],
most important to ATP depletion and pH imbalance. Substitutions of RIF, INH, or
PZA with DRQ TMC207 hasten activity [80].
Purine Analogs
The 9-Benzylpurines, with a variety of substituents on 2, 6, and/or 8 positions,
have high inhibitory activities against Mtb. One compound, carrying trans-styryl or
aryl substituents at 6 positions and generally chlorine in 2 positions tends to increase
the in vitro activity and has MIC of 0.78 mg/mL [81]. The anti-TB activity of 6-
arylpurines [82] and 9-sulphonylated or sulphenylated-6-mercaptopurines are also
known [83].
Benzylpurines
The 9-benzylpurines, 2-chloro-4(2-furanyl)-9-benzylpurine was potently
inhibited Mtb H37Rv in-vitro with a MIC value of 0.78 μg/ml with low cytotoxicity
towards VERO cells (IC50 value-8.1 μg/ml) selectivity index (MIC/IC50) of 10.4 [4].
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Thiolactomycin Analogues
Naturally occurring (5R)-thiolactomycin (TLM) exhibits potent in vivo activity
against many pathogenic bacteria, and Mtb [84]. TLM inhibited bacterial and plant
type II fatty acid synthases (FAS-II) but not inhibited mammalian or yeast type I
fatty acid synthases (FAS-I) [85]. In E. coli, it inhibited both β-ketoacyl-ACP
synthase I to III and acetyl coenzyme A (CoA): ACP transacylase activities [86, 87].
The TLM was the first example of naturally occurring thiolactone to displayed
antibiotic action. The TLM analogs have improved activity against whole cells of
pathogenic Mtb strains [88]. The TLM analogs act by the inhibition of the mycolate
synthase, an enzyme involves in the biosynthesis of the Mtb cell wall.
This has led to the hope that inhibitors of the TLM target enzyme, FAS-II, are
potentially important in the treatment of malaria [89], trypanosomiasis, or sleeping
sickness [90], and a range of bacterial indications including TB. It also blocks long-
chain mycolate synthesis in a dose-dependent mode [91]. The TLM is active in vitro
against an extensive range of strains of Mtb, including INH- resistant, although at
somewhat high concentrations. For example, complete inhibition of growth on solid
media of the strain Mtb Erdman is seen at 25 μg/ml. The TLM itself as an anti-TB
agent [92] and racemic mixtures, e.g. compounds (A) and (B), which are accounted
to have superior activity than the parent in inhibiting Mtb H37Rv in-vitro.
Mefloquine Analogues
The antimalarial agent mefloquine and its analogs have activity against a range
of bacteria including Mtb [93]. A series of quinolinemethanol analogs, two com-
pounds, WR-3016, and WR-3017, exhibited potent inhibitory effects in vitro in the
M. avium complex-1 (MAC) assay with MIC50 values of 1 and 2 μg/ml respectively,
compared to 16 μg/ml for mefloquine. Other mefloquine analogs, two enantiomers
of mefloquine and might be valuable to test some representative 4-aminoquinoline
antimalarials such as chloroquine [94]. Another compound desbutylhalofantrine
(3) is in progress for its antimalarial activities with an advantage over the parent
drug halofantrine of lesser cardiotoxicity.
Deazapteridines
Some 2,4-diamino-5-deazapteridine derivatives, SRI-20094 has potent inhibi-
tion of MM6 cells infected with MAC strain NJ3440 with a MIC value 0.13 μg/ml.
SRI-20094 inhibits the dihydrofolate reductase (DHFR) of the MAC, with an IC50
value 1.0 nM as compared to 4100, 1.4 and 1.0, nM for the trimethoprim,
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piritrexim, and trimetrexate,. It confirmed limited inhibition for human DHFR
having an IC50 value 7300 nM. SRI-20094 is a value for the M. avium infection and
in particular for HIV co-infected persons. Other close analogs were highly active
against Mtb with MICs of 0.1 mg/l [95].
1,2,4-Benzothiadiazines
The 1,2,4-benzothiadiazine dioxides have a close relation to sulfonamide and
could be considered as cyclic sulfonamides. These compounds exhibited antimicro-
bial activity [96]. The 1,2,4-benzothiadiazines were explored by incorporating other
heterocyclic rings like pyridine and pyrazine moieties (4 and 5) and these com-
pounds were exhibited interesting anti-TB activity [97].
Other Molecules
Several other molecules like pyrroles (6) [98], quinoxaline-1,4-dioxides (7) [99],
and alkylsulfinyl amides (8) [100] have been tested for their anti-TB activity. In the
analysis of the constant MDR-TB problem, new drugs should concentrate on differ-
ent targets, including the reduction of TB therapy [101], with negligible toxicity
and thus structures based on this lead could provide a novel class of anti-TB drugs.
Benzoxazine derivatives
Some 6-chloro-3-phenyl-4-thioxo-2H-1,3-benzoxazine-2(3H)-ones (9) and 6-
chloro-3-phenyl-2H-1,3-benzoxazine-2,4(3H)-dithiones (10) have potent anti-TB
activity against Mtb (MIC values 0.5 mcmol/l), M. avium (16 and 16 μmol/l), M.
kansasii (2 and 2 μmol/l), and M. kansaii (1 and 0.5 μmol/l), compared with MIC
values of 4, 8, 500 and 500 μmol/l for INH after 14 days [4].
Diterpenoids
Marine products gorgonian coral Pseudopterogorgia elisabethae from the West
Indian have the anti-TB activity of two active diterpenoid alkaloidal compounds,
secopseudopteroxazole and pseudo-pteroxazole [4, 71]. The pseudopteroxazole
against Mtb H37Rv was claimed to be a powerful inhibitor giving 97% growth
inhibition at 12.5 μg/ml even as seco-pseudopteroxazole was rather less active. Some
of these derivatives are significantly more active than the marine diterpenoids (11)
with the MIC value of Mtb H37Rv = 0.46 μg/ml.
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Tryptanthrin derivatives
Tryptanthrin is an indoloquinazolinone containing alkaloid and evaluated
against different strains of Mtb including the drug-sensitive Mtb H37Rv strain. The
MIC value of tryptanthrin was 1.0 μg/ml compared to the MIC value of INH was
0.03 μg/ml. When evaluated against a section of MDR-TB strains, even as
tryptanthrin sustain its effectiveness (MIC = 0.5-1 μg/ml), INH had declined activ-
ity with MIC value 4-16 μg/ml. Many derivatives have been tested for their poten-
tial in TB treatment like PA-505 having powerful in vitro activity towards Mtb
H37Rv-MIC 0.015 μg/ml and had only modest actions in reducing Mtb in the spleen
of infected mice when given orally at 50 mg/kg/day for ten days [102].
Clofazimine or Tetramethylpiperidino (TMP) Phenazines Analogues
The tetramethyl piperidine substituted phenazines B4169 and B4128 (TMP
phenazines) have possessed significantly activity against Mtb, including MDR clin-
ical strains than clofazimines [103]. Recently, new conjugates of phenazine with
phthalimido and naphthalimido moieties (12) have anti-TB activity [33]. Some
phenazine hybrids have shown potential inhibition of Mtb ATCC 27294 as well as
their clinical isolates (both sensitive and resistant). There is a potential to design
new phenazine hybrids for the research and development of new anti-TB agents
[14]. The anti-TB effects of tetramethyl piperidinophenazine derivatives are closely
related to the clofazimine. The intra- and extracellular effects of these drugs were
compared to clofazimine and RIF against Mtb H37Rv. The B4169 has effectively
inhibited the bacterium with a MIC value of 0.015 μg/ml; the equivalent value for
clofazimine was 0.06 μg/ml. These compounds were more active than clofazimine
against a series of Mtb isolates plus MDR-TB strains. Besides, some derivatives,
B4128, exhibited significant intracellular activity (60% inhibition of growth) at
0.001 μg/ml against Mtb infected monocyte-derived macrophages and were better
to both clofazimine and RIF drug [14, 15].
Phenazine B4157
The B4157 is a phenazinamine derivative, closely related to clofazimine, has a
potential action for TB. In vitro, clofazimine and B4157 were screened against
various Mtb strains, most of resistance strains, and all were vulnerable to B4157
including which were resistance to clofazimine. The MICs value of B4157 and
clofazimine at which 90% of strains inhibited were 0.12 and 1.0 μg/ml. However,
C57BL against Mtb at 20 mg/kg, clofazimine was slightly better to B4157 [4, 15].
Toluidine Derivatives
Some analogs of toluidines have attractive in vitro activity against Mtb 103471,
the best compound (14), having MICs values 4 μg/ml-cf MICs of INH, 0.25 μg/ml,
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and SM, 0.5 μg/ml. However, these amines will undergo rapid metabolic degrada-
tion, possibly toxic metabolites [4, 15].
Saccharides
The arabinose disaccharide SR-9581 is in vitro effective against Mtb, with a MIC
value 4 μg/ml. It reduced the viability of Mtb 76.1%, 97.8%, and 99.9% at 8, 16, and
32 μg/ml in 3 days. Another saccharide, an arabinofuranoside oligosaccharide (14),
substrate for mycobacterial arabinosyltransferases, both compounds can disrupt
biosynthesis of Mtb cell wall [104, 105].
Oxazolidinones (Linezolid)
The Oxazolidinones are a class of broad-spectrum antibiotic compounds. They
inhibit protein synthesis through binding to the 50S subunit of ribosomes.
Oxazolidinones had considerable activities against Mtb in-vitro in mice [106].
Oxazolidinones are less promising due to their toxicities and high-cost value
[107, 108].
Oxazolidinones PNU 100480 and AZD 2563
They have bacteriostatic activity against various human pathogens together with
drug-resistant microorganisms [109, 110]. The oxazolidinones have activity against
Mtb and linezolid (U-100766) inhibiting MDR isolates in vitro at 2 μg/ml [111].
Oxazolidinones having a thiomorpholine group in place of the morpholine group
present in linezolid has mainly active against Mtb with MICs value 0.125 μg/ml
[112]. PNU-100480 was also tested in a murine model against ten strains of Mtb in
comparison to linezolid and INH. PNU-100480 was found equivalent to INH and
more active than linezolid [106].
Calanolides
Calanolide A is a naturally pyranocoumarin that has double action against TB
and HIV infections. This compound is an inhibitor of the HIV-1 reverse transcrip-
tase enzyme. It also exhibits good in vitro effects towards Mtb. In a beginning
test of its activity, calanolide A was analogous to the positive control INH and
staying effective against RIF and SM resistant TB strains. Calanolide A decreasing
the dependency upon acquiring the material from limited natural resources [4, 27]
and some compounds, e.g. (15), have patented for their anti-TB activities.
Calanolide B, which distinct calanolide A, is existing in considerable quantities
from renewable natural sources, e.g. from Calophyllum seed oil, [113] has a
similar range of activity to calanolide A against Mtb and may be an additional cost-
effective treatment.
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Poloxamer 315 (CRL-1072)
Poloxamer 315 is a methyl oxirane surfactant polymer that shows to disrupt the
cell membranes of microorganisms or their intracellular components. The purified
polymer is effective against Mtb and M. avium. In vitro effect against Mtb showed
MIC values 3.1–6.2 μg/ml even as, in a macrophage assay, these go down to 0.92 to
1.25 μg/ml. This compound was effective against strains of Mtb resistant to INH,
SM, and RIF [114].
Niclosamide
The anthelmintic drug niclosamide was found to have anti-TB activity in vitro
(MIC 0.5-1 μg/ml) against Mtb H37Ra. However, niclosamide is useful for the
treatment of human tapeworm infections; it is not absorbed to any significant
extent from the intestine [115].
Mikasome
The liposome-encapsulated drug for the anti-TB activity, Mikasome, is useful
againstM. avium infections in vitro and in vivo. In animals, Mikasome formed 7-fold
higher peak plasma levels compared to free drug amikacin (i.v.). The AUC was 150-
fold higher with the liposomal substance and a single dose of liposomal amikacin
formed therapeutic levels of antibiotics for more than 72 hr. The pilot Phase II
studies showed that MiKasome was capable to resolveMtb infections who had failed
conventional therapies [4, 14].
Fulleropyrrolidines
A series of fullerene analogs, compound (2.158) exhibited anti-TB activity. It
inhibited the growth of a human clinical isolate, Mtb H6/99, MIC value of 5 μg/ml,
and Mtb H37Rv MIC value of 50 μg/ml. Some fullerene derivatives have also
exhibited in-vitro activity against the HIV protease contributing to the tantalizing
option of combined actions towards both AIDS and TB [2–4].
Pyrrole LL- 3858
Some pyrroles analogs were effective in-vitro against the standard and drug-
sensitiveMtb strains [116]. Compounds LL-3858 was exhibited a higher bactericidal
effect than INH when given as monotherapy to infected mice.
Dipiperidine SQ-609
Dipiperidine SQ-609 is structurally dissimilar to the existing anti-TB drug. It
destroyed Mtb by interfering with cell wall biosynthesis. The antimicrobial effect
has been established in vivo in mice models [117–119].
Pleuromutilins
The pleuromutilins is a novel natural antibiotic. They interfere with protein
synthesis by binding to the 23S rRNA and consequently inhibiting the formation of
a peptide bond [118]. The cross-resistance might happen between pleromutilins and
oxazolidinones [119]. Pleuromutilins have been revealed to in-vitro inhibition of the
Mtb growth. The pleuromutilin compound is active against MDR-TB and permitted
shortening of the treatment time.
ATP Synthase inhibitor FAS20013
The FAS20013 belongs to the β-sulphonylcarboxamide analogs. FAS20013
destroys more organisms in a 4-hour exposure than INH or RIF can throughout a
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12- to 14-day exposure. This compound is especially effective in killing MDR-TB
strains that are resistant to currently used multiple drugs. The greater effect of
FAS20013 compared to current anti-TB drugs in terms of its ability to sterilize TB
injuries and kill latent TB strains. The FAS20013 has its efficiency in mice with no
serious adverse effects and it is up to 100% bioavailable when orally used. The
compound is acted by inhibition of ATP synthase [120].
Diamine SQ-109
Diamine SQ-109 was developed as a second-generation drug from the first-line
drug ethambutol (EMB). When examined in a low-dose infection model of TB in
mice, SQ-109 at 1 mg/kg was as efficient as EMB at 100 mg/kg. However, SQ-109
did not prove improved efficacy at higher doses (10 mg/kg; 25 mg/kg) and was less
efficient than INH [121]. The SQ-109 is effictive against MDR-TB, together with
those that are EMB-resistant.
Nitrofuranylamides
The Mtb is relatively vulnerable to Nitro-containing compounds [122].
Nitrofuranylamide (16) was accepted in testing for UDP-Gal mutase inhibition.
A prolonged set of nitrofuranylamides was tested for anti-microbial activity.
This led to the recognition of several nitrofuranylamides with activity effective
against Mtb [123].
6. Conclusion
Tuberculosis (TB) is a chronic infectious disease caused by M. tuberculosis. Anti-
TB drugs developed since the 1940s and their discovery resistance also developed
against them. Acquired and primary drug resistances are the common pathways for
the development of anti-TB drug resistance. Anti-TB drugs mainly act on protein
synthesis, folic acid synthesis, mycolic acid synthesis, DNA synthesis, and ATP
synthase. These anti-drugs cause bacteriostatic and/or bactericidal effects on the
mycobacterium. The major resistance mechanism is the mutation of the target gene
responsible for the action of anti-TB drugs. Anti-TB drug resistance produces a
destructive effect on public health. Therefore, the advance study should be
conducted in the areas of finding new targets for the development of novel anti-TB
drugs.
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